company background image
BTMD logo

biote NasdaqGM:BTMD Stock Report

Last Price

US$5.87

Market Cap

US$370.3m

7D

-8.3%

1Y

9.7%

Updated

27 Mar, 2024

Data

Company Financials +

biote Corp. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for biote
Historical stock prices
Current Share PriceUS$5.87
52 Week HighUS$8.22
52 Week LowUS$3.65
Beta0.89
1 Month Change5.01%
3 Month Change16.93%
1 Year Change9.72%
3 Year Changen/a
5 Year Changen/a
Change since IPO-41.59%

Recent News & Updates

Recent updates

biote initiated as a buy at Truist on leadership in hormone optimization; sees 138% upside

Sep 27

Biote partners with IMAC Holdings

Sep 07

Shareholder Returns

BTMDUS PharmaceuticalsUS Market
7D-8.3%1.2%0.4%
1Y9.7%25.8%28.8%

Return vs Industry: BTMD underperformed the US Pharmaceuticals industry which returned 23.9% over the past year.

Return vs Market: BTMD underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is BTMD's price volatile compared to industry and market?
BTMD volatility
BTMD Average Weekly Movement12.7%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: BTMD's share price has been volatile over the past 3 months.

Volatility Over Time: BTMD's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2012194Terry Weberhttps://biote.com

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.

biote Corp. Fundamentals Summary

How do biote's earnings and revenue compare to its market cap?
BTMD fundamental statistics
Market capUS$370.35m
Earnings (TTM)US$3.32m
Revenue (TTM)US$185.36m

60.4x

P/E Ratio

1.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BTMD income statement (TTM)
RevenueUS$185.36m
Cost of RevenueUS$57.88m
Gross ProfitUS$127.48m
Other ExpensesUS$124.17m
EarningsUS$3.32m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.097
Gross Margin68.78%
Net Profit Margin1.79%
Debt/Equity Ratio-308.9%

How did BTMD perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.